1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Eli Lilly and Company

Eli Lilly and Company

LLY
Eli Lilly and CompanyUS flagNew York Stock Exchange
1,240.34
USD
-16.69
- -
1.17TMarket Cap
Eli Lilly and Company
LLY
(New York Stock Exchange)

Recent

price

1,240.34

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
20.87
21.8
19.72
20.7
17.66
18.06
19.28
18.99
20.91
23.31
25.65
29.69
30.04
37.94
50.19
72.84
89.12
Revenue per Share
4.58
3.9
3.57
4.19
2.15
2.18
2.49
-0.19
3.14
8.69
6.47
5.85
6.57
5.83
11.8
23.07
29.88
Basic EPS, GAAP
5.13
4.97
3.72
4.16
2.6
1.21
3.41
3.28
2.44
3.64
4.67
5.65
4.84
-3.5
0.46
6.67
15.17
Free Cash Flow per Basic Share
1.96
1.96
1.91
1.9
1.89
1.92
1.96
2.08
2.25
2.52
2.81
3.24
3.72
4.52
5.21
6.02
6.47
Dividend per Share
10.78
11.7
12.88
15.79
13.84
13.18
12.72
10.54
9.3
2.72
5.9
9.42
11.21
11.98
15.81
29.65
38
Book Value per Share
6.6
7.27
8.73
11.91
9.66
4.97
5.16
2.9
7
-8.03
-5.83
-2.73
-0.66
-1.19
2.51
15.77
7.76
Tangible Book Value per Share
1,106
1,114
1,146
1,117
1,111
1,105
1,101
1,052
1,028
958
957
954
950
899
898
895
894
Basic Weighted Avg Shares
23,076
24,286
22,603
23,113
19,616
19,959
21,222
19,974
21,493
22,320
24,540
28,318
28,541
34,124
45,043
65,179
79,666
Sales/Revenue/Turnover
29.35
26.01
22.19
24
16.97
18
17.31
20.03
26.92
25.94
28.36
26.99
29.01
30.26
37.83
45.56
49.72
Operating Margin (%)
1,328
1,374
1,462
1,446
1,379
1,428
1,497
1,567
1,609
1,233
1,324
1,548
1,522
1,527
1,767
1,997
2,099
Depreciation Expense
5,070
4,348
4,089
4,685
2,390
2,408
2,738
-204
3,232
8,318
6,194
5,582
6,245
5,240
10,590
20,640
26,711
Net Income, GAAP
22.31
18.73
24.4
20.45
20.32
13.68
18.86
103.75
14.39
11.93
14.33
9.32
8.25
20.05
16.48
19.79
20.49
Effective Tax Rate (%)
21.97
17.9
18.09
20.27
12.19
12.07
12.9
-1.02
15.04
37.27
25.24
19.71
21.88
15.36
23.51
31.67
33.53
Profit Margin (%)
7,739
5,317
4,649
4,188
2,187
4,344
4,115
4,666
8,662
1,934
4,980
3,400
896
-1,566
4,364
20,401
16,931
Working Capital
6,770
5,465
5,519
4,200
5,333
7,972
8,368
9,940
9,196
13,818
16,587
15,346
14,738
18,321
28,527
40,868
47,858
LT Debt
12,413
13,536
14,774
17,641
15,388
14,590
14,080
11,668
10,909
2,699
5,825
9,155
10,775
10,864
14,272
26,535
33,879
Total Equity
28.96
25.11
17.85
19.52
10.88
12.97
12.59
-0.6
20.9
25.67
29.05
28.27
28.34
25.98
33.89
40.74
40.9
Return on Invested Capital (%)
29.35
22.57
20.69
22.3
10.85
11.08
12.3
-0.86
14.79
44.21
32.16
24.31
24.69
17.84
26.76
35.3
36.53
Return on Capital (%)
46.2
33.49
28.89
28.92
14.49
16.09
19.16
-1.59
30.18
133.78
150.18
76.35
63.63
48.92
84.84
101.36
102.44
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,635
4,000
7,050
LT Borrowings
40,868
39,370
47,858
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
895
894
892
Market Capitalization
961,624
821,814
1,069,292

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
55,629
54,835
64,672
Cash, Cash Equivalents & STI
7,268
5,282
8,950
Accounts Receivable, Net
17,760
18,429
20,083
Inventories
13,744
14,529
16,793
Total Current Liabilities
35,228
36,634
47,741
Payables & Accruals
22,761
22,576
27,234
ST Debt
1,635
4,000
7,050
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.64%
38.59%
85.92%
Free Cash Flow
127.74%
212.97%
1,340.58%
Net Income, GAAP
-146.26%
36.58%
94.9%
Sales/Revenue/Turnover
13.43%
22.49%
44.7%
Total Cash Common Dividend
9.88%
14.91%
15.04%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,768
11,303
11,439
13,533
45,043
2025
12,729
15,558
17,601
19,292
65,179
2026
19,799
22,974
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.49
3.3
1.08
4.91
11.8
2025
3.07
6.3
6.23
7.42
23.07
2026
8.28
7.96
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.3
1.3
1.3
1.3
5.21
2025
1.5
1.5
1.5
1.5
6.02
2026
1.73
1.73
- -
- -
- -
Similar Companies
Roche Holding AG (ROG.SW)
Bristol-Myers Squibb Company (BRM.DE)
NGL Fine-Chem Limited (NGLFINE.BO)
Kopran Limited (KOPRAN.BO)
Amgen Inc. (AMGN)
Novo Nordisk A/S (NOVO.TO)
Business

Company News

Company News APIChatGPT

  • marketbeat.com

    The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning

  • marketbeat.com

    What a Mixed Midterm Result Could Mean for These 2 Health Care ETFs

  • reuters.com

    Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech

  • prnewswire.com

    Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

  • fool.com

    Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It

  • gurufocus.com

    Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

  • prnewswire.com

    Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

  • fool.com

    Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy.

  • fool.com

    If a Stock Market Crash Is Coming, History Says These 3 ETFs Are the Smartest Buys

  • fool.com

    Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher

  • 247wallst.com

    A $1,000 Investment in Eli Lilly Became $18,637. The Obesity Boom Changed Everything

  • benzinga.com

    Eli Lilly Says New Drug Drives Comprehensive Disease Control in Ulcerative Colitis Patients

  • prnewswire.com

    Lilly confirms date and conference call for third-quarter 2026 financial results announcement

  • prnewswire.com

    New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year

  • seekingalpha.com

    Polen Focus Growth Portfolio Q3 2026 Portfolio Update

  • defenseworld.net

    Eli Lilly and Company $LLY Stock Sold by Fairfield Financial Advisors LTD

  • schaeffersresearch.com

    Stocks Struggling With Another Bond Yield Spike

  • gurufocus.com

    A Look at Eli Lilly and Co (LLY) After 1.4% Decline -- GF Value $1575.10 vs Price $1166.51

  • zacks.com

    Here's Why Eli Lilly (LLY) Fell More Than Broader Market

  • fool.com

    Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?